01Atossa Therapeutics reported Q2 2026 earnings per share of -$0.95, beating the consensus estimate of -$1.09 by $0.14 per share, representing a 12.8% positive surprise.
02The company's stock trades at $2.36 with a market capitalization of $116.9 million as of the earnings report date.
03Atossa has beaten earnings estimates for three consecutive quarters, with Q4 2025 showing a 97.3% surprise, Q1 2026 showing a 9.0% surprise, and Q2 2026 showing a 12.8% surprise.
04The company is a healthcare company that continues to report negative earnings per share, indicating it is not yet profitable.
Earnings Results
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly earnings results on August 07, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.95, beating the consensus estimate of $-1.09 by $0.14 per share. Revenue came in at , meeting the estimate of .
Company Overview
Atossa Therapeutics's stock moved following the earnings release. The stock currently trades at $2.36 with a market capitalization of $116.9M.
Atossa Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 13% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Atossa Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.